Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.52 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12622076 | 0.95 | L3MBTL1 (0.52) | HCRTR1HCRTR2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL13035959 | 0.91 | HCRTR1 (0.58) | HCRTR1HCRTR2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL12626946 | 0.87 | HCRTR1 (0.53) | HCRTR1HCRTR2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL12626158 | 0.85 | LMNA (0.61) | ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL12663594 | 0.84 | L3MBTL1 (0.52) | HCRTR1HCRTR2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL12626027 | 0.83 | ALDH1A1 (0.49) | HCRTR1HCRTR2ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL25493808 | 0.82 | L3MBTL1 (0.53) | HCRTR1HCRTR2ALDH1A1L3MBTL1USP2 | |
| SCHEMBL18061825 | 0.82 | L3MBTL1 (0.48) | HCRTR1HCRTR2ALDH1A1L3MBTL1 | |
| SCHEMBL12626207 | 0.81 | L3MBTL1 (0.61) | ALDH1A1L3MBTL1 | |
| SCHEMBL12663591 | 0.81 | ALDH1A1 (0.53) | ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661580-B2 | Method of inhibiting tau phosphorylation | CASSAVA SCIENCES, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | PAIN THERAPEUTICS, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9500640-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS, INC. (US) | 2016-11-22 | — | — | US | disclosed |
| US-9433604-B2 | Method for inhibiting growth of cancer cells | PAIN THERAPEUTICS INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9354223-B2 | Alzheimer's disease assay in a living patient | PAIN THERAPEUTICS INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | PAIN THERAPEUTICS, INC. | 2015-05-28 | — | — | US | disclosed |
| US-20140017698-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | WANG HOAU-YAN (US) | 2014-01-16 | — | — | US | disclosed |
| US-20140017699-A1 | ALZHEIMER'S DISEASE ASSAY IN A LIVING PATIENT | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | CASSAVA SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018341-A1 | METHOD OF INHIBITING TAU PHOSPHORYLATION | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885ALDH1A1 4388/4885 |
| US-11661580-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885ALDH1A1 4388/4885 |
| US-10017736-B2 | Method of inhibiting tau phosphorylation | FLNA, FLNB, MAPT | HCRTR1 2888/4885HCRTR2 3501/4885ALDH1A1 4388/4885 |
| US-20150148318-A1 | METHOD FOR INHIBITING GROWTH OF CANCER CELLS | FLNA, FLNB, FSCN1 | HCRTR1 3430/4885HCRTR2 3778/4885ALDH1A1 3552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.